CPT | |
---|---|
HCPCS | |
S2120 | Low density lipoprotein (LDL) apheresis using heparin-induced extracorporeal LDL precipitation |
ICD-10 Diagnosis | |
E78.00 | Pure hypercholesterolemia, unspecified |
Pheresis of Plasma, Single 2016 2017 2018 2019 2020 2021 Billable/Specific Code ICD-10-PCS 6A550Z3 is a specific/billable code that can be used to indicate a procedure.
Other disorders of plasma-protein metabolism, not elsewhere classified. E88.09 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM E88.09 became effective on October 1, 2019.
2016 2017 2018 2019 Billable/Specific Code. B96.89 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Oth bacterial agents as the cause of diseases classd elswhr. The 2018/2019 edition of ICD-10-CM B96.89 became effective on October 1, 2018.
2018/2019 ICD-10-CM Diagnosis Code Z41.9. Encounter for procedure for purposes other than remedying health state, unspecified. Z41.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
2022 ICD-10-PCS Procedure Code 6A550Z3: Pheresis of Plasma, Single.
ICD-10 code Z51. 81 for Encounter for therapeutic drug level monitoring is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Encounter for examination of potential donor of organ and tissue. Z00. 5 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
ICD-10 code E88. 09 for Other disorders of plasma-protein metabolism, not elsewhere classified is a medical classification as listed by WHO under the range - Endocrine, nutritional and metabolic diseases .
V58. 69 - Long-term (current) Use of Other Medications [Internet]. In: ICD-10-CM.
Other long term (current) drug therapy The 2022 edition of ICD-10-CM Z79. 899 became effective on October 1, 2021. This is the American ICD-10-CM version of Z79.
A transplant complication is only coded if the function of the transplanted organ is affected. Patients may still have some form of CKD even after transplant. Malignancy of a transplanted organ should be coded as a transplant complication followed by the code C80. 2, Malignant neoplasm associated with transplanted ...
Liver transplant status4: Liver transplant status.
ICD-10 Code for Atherosclerotic heart disease of native coronary artery without angina pectoris- I25. 10- Codify by AAPC.
Other disorders of plasma-protein metabolism, not elsewhere classified. E88. 09 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM E88.
E88. 9 - Metabolic disorder, unspecified | ICD-10-CM.
A blood volume test (also called a plasma volume test or a red cell mass test) is a nuclear lab procedure used to measure the volume (amount) of blood in the body. The test also measures the volume of plasma and of red cells in the blood.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes. Primary malignant neoplasms overlapping site boundaries.
One type is waldenstrom's macroglobulinemia, which is a type of cancer. A clonal neoplasm of small b-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum igm paraprotein.
Plasmapheresis refers to a procedure in which the plasma is separated from the blood either by centrifugation or membrane filtration.
Waldenstrom's macroglobulinemia, prophylactic treatment in persons with IgM greater than or equal to 5000 mg/dL while on rituximab or ofatumumab mg/dL, to avoid aggravation of serum viscosity on the basis of IgM flare related to rituximab or ofatumumab.